New drug combo aims to shrink lung tumors before surgery
NCT ID NCT05247684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing a new drug called AK112, alone or with chemotherapy, in people with resectable non-small cell lung cancer. The goal is to see if giving the treatment before and after surgery can help shrink tumors and prevent the cancer from coming back. The study involves 90 participants and focuses on safety and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK112 (a bispecific antibody targeting PD-1 and VEGF), carboplatin, cisplatin, paclitaxel
What this could lead to
If successful, this could offer a new treatment option to shrink lung tumors before surgery and reduce the chance of cancer returning afterward.
What could go wrong
This is an early phase II trial with only 90 participants, so results may not apply to everyone. Side effects from the drug combination could be significant, and the treatment may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China